29 results on '"Awrey, S."'
Search Results
2. 925 STAT1 inhibition restored chemotherapy sensitivity in cisplatin/gemcitabine resistant bladder cancer
- Author
-
Hayashi, T., primary, Seiler, R., additional, Bell, R., additional, Ettinger, S., additional, Wang, K., additional, Goriki, A., additional, Oo, H.Z., additional, Awrey, S., additional, Gust, K., additional, Jaeger, W., additional, Todenhöfer, T., additional, Altamirano-Dimas, M., additional, Matsubara, A., additional, Collins, C., additional, and Black, P., additional
- Published
- 2016
- Full Text
- View/download PDF
3. 791 Notch2-HEY axis promotes tumour growth in bladder cancer through cell cycle progression and de-differentiation
- Author
-
Hayashi, T., primary, Goriki, A., additional, Oo, H.Z., additional, Seiler, R., additional, Todenhofer, T., additional, Jaeger, W., additional, Awrey, S., additional, Altamirano-Dimas, M., additional, Fazli, L., additional, Matsubara, A., additional, and Black, P., additional
- Published
- 2016
- Full Text
- View/download PDF
4. 522 Targeting HER2 with trastuzumab-DM1 (T-DM1) is highly effective in preclinical models of HER2-overexpressing bladder cancer
- Author
-
Hayashi, T., primary, Jäger, W., additional, Moskalev, I., additional, Awrey, S., additional, Li, N., additional, Fazli, L., additional, Yasui, W., additional, Matsubara, A., additional, and Black, P.C., additional
- Published
- 2014
- Full Text
- View/download PDF
5. 39 Notch2 promotes bladder cancer progression: Pre-clinical rationale for a novel targeted therapy
- Author
-
Hayashi, T., primary, Gust, K.M., additional, Jäger, W., additional, Awrey, S., additional, Li, N., additional, Altamirano-Dimas, M., additional, Buttyan, R., additional, Fazli, L., additional, Matsubara, A., additional, and Black, P.C., additional
- Published
- 2014
- Full Text
- View/download PDF
6. 516 Targeting IGF-BP2 and 5 with the bispecific antisense oligodeoxynucleotide OGX-225 in chemoresistant bladder cancer
- Author
-
Jäger, W., primary, Hayashi, T., additional, Ischia, J., additional, Janßen, C., additional, Awrey, S., additional, Fazli, L., additional, Gleave, M.E., additional, and Black, P.C., additional
- Published
- 2014
- Full Text
- View/download PDF
7. 403 Patient-derived primary xenografts in the preclinical development of novel targeted therapies for bladder cancer
- Author
-
Jäger, W., primary, Xue, H., additional, Janßen, C., additional, Tetsutaro, H., additional, Awrey, S., additional, Fazli, L., additional, Li, E., additional, Wang, Y.Z., additional, and Black, P.C., additional
- Published
- 2014
- Full Text
- View/download PDF
8. 50 Silencing Notch-1 and Notch-3 promotes epithelial-to-mesenchymal transition (EMT) and self-renewal potential in human bladder cancer
- Author
-
Jaeger, W., primary, Hayashi, T., additional, Awrey, S., additional, Gust, K.M., additional, Cordonnier, T., additional, Li, N., additional, Buttyan, R., additional, Van Der Kwast, T.H., additional, Van Rhijn, B.W., additional, Thüroff, J.W., additional, and Black, P.C., additional
- Published
- 2013
- Full Text
- View/download PDF
9. 74 LATE ENDOCRINE TOXICITY OF RADIATION THERAPY IN CHILDREN TREATED FOR MEDULLOBLASTOMA OR EPENDYMOMA
- Author
-
Bahl, G., primary, Urbach, S., additional, Bartels, U., additional, Hodgson, D., additional, Millar, B.A., additional, Parent, A., additional, Le, L., additional, Awrey, S., additional, and Laperriere, N., additional
- Published
- 2009
- Full Text
- View/download PDF
10. Endocrine complications in children treated for medulloblastoma or ependymoma using radiation therapy. Outcomes in the CT-planning era
- Author
-
Bahl, G., primary, Urbach, S., additional, Bartels, U., additional, Hodgson, D. C., additional, Millar, B., additional, Parent, A., additional, Le, L., additional, Awrey, S., additional, and Laperriere, N., additional
- Published
- 2009
- Full Text
- View/download PDF
11. 40 Application of a radiographically-precise technique to plan, verify and administer craniospinal irradiation in the supine position
- Author
-
Lau, M., primary, Guscott, H., additional, Heaton, R., additional, Laperriere, N., additional, Millar, B-A., additional, Awrey, S., additional, and Guscott, J., additional
- Published
- 2006
- Full Text
- View/download PDF
12. Paediatric radiation therapy without anaesthesia - Are the children moving?
- Author
-
Ritchie T, Awrey S, Maganti M, Chahin R, Velec M, Hodgson DC, Dama H, Ahmed S, Winter JD, Laperriere N, and Tsang DS
- Subjects
- Humans, Child, Prospective Studies, Movement, Cone-Beam Computed Tomography methods, Radiotherapy Planning, Computer-Assisted methods, Anesthesia, Radiotherapy, Image-Guided methods
- Abstract
Purpose: Children who require radiation therapy (RT) should ideally be treated awake, without anaesthesia, if possible. Audiovisual distraction is a known method to facilitate awake treatment, but its effectiveness at keeping children from moving during treatment is not known. The aim of this study was to evaluate intrafraction movement of children receiving RT while awake., Methods: In this prospective study, we measured the intrafraction movement of children undergoing treatment with fractionated RT, using pre- and post-RT cone beam CT (CBCT) with image matching on bony anatomy. Study CBCTs were acquired at first fraction, weekly during RT, and at last fraction. The primary endpoint was the magnitude of vector change between the pre- and post-RT scans. Our hypothesis was that 90 % of CBCT acquisitions would have minimal movement, defined as <3 mm for head-and-neck (HN) treatments and <5 mm for non-HN treatments., Results: A total of 65 children were enrolled and had evaluable data across 302 treatments with CBCT acquisitions. Median age was 11 years (range, 2-18; 1st and 3rd quartiles 7 and 14 years, respectively). Minimal movement was observed in 99.4 % of HN treatments and 97.2 % of non-HN treatments. The study hypothesis of >90 % of evaluations having minimal movement was met. Children who were age >11 years moved less at initial evaluation but tended to move more as a course of radiation progressed, as compared to children who were younger., Conclusion: Children receiving RT with audiovisual distraction while awake had small magnitudes of observed intrafraction movement, with minimal movement in >97 % of observed RT fractions. This study validates methods of anaesthesia avoidance using audiovisual distraction for selected children., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
13. Pediatric Radiation Therapy at the Princess Margaret Cancer Centre.
- Author
-
Ritchie T and Awrey S
- Subjects
- Humans, Child, Neoplasms radiotherapy
- Published
- 2023
- Full Text
- View/download PDF
14. Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors.
- Author
-
Radaeva M, Li H, LeBlanc E, Dalal K, Ban F, Ciesielski F, Chow B, Morin H, Awrey S, Singh K, Rennie PS, Lallous N, and Cherkasov A
- Subjects
- Androgen Antagonists, DNA, Humans, Ligands, Male, Morpholines, Androgen Receptor Antagonists pharmacology, Receptors, Androgen metabolism
- Abstract
The mutation-driven transformation of clinical anti-androgen drugs into agonists of the human androgen receptor (AR) represents a major challenge for the treatment of prostate cancer patients. To address this challenge, we have developed a novel class of inhibitors targeting the DNA-binding domain (DBD) of the receptor, which is distanced from the androgen binding site (ABS) targeted by all conventional anti-AR drugs and prone to resistant mutations. While many members of the developed 4-(4-phenylthiazol-2-yl)morpholine series of AR-DBD inhibitors demonstrated the effective suppression of wild-type AR, a few represented by 4-(4-(3-fluoro-2-methoxyphenyl)thiazol-2-yl)morpholine (VPC14368) exhibited a partial agonistic effect toward the mutated T878A form of the receptor, implying their cross-interaction with the AR ABS. To study the molecular basis of the observed cross-reactivity, we co-crystallized the T878A mutated form of the AR ligand binding domain (LBD) with a bound VPC14368 molecule. Computational modelling revealed that helix 12 of AR undergoes a characteristic shift upon VPC14368 binding causing the agonistic behaviour. Based on the obtained structural data we then designed derivatives of VPC14368 to successfully eliminate the cross-reactivity towards the AR ABS, while maintaining significant anti-AR DBD potency.
- Published
- 2022
- Full Text
- View/download PDF
15. Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors.
- Author
-
Chafe SC, Vizeacoumar FS, Venkateswaran G, Nemirovsky O, Awrey S, Brown WS, McDonald PC, Carta F, Metcalfe A, Karasinska JM, Huang L, Muthuswamy SK, Schaeffer DF, Renouf DJ, Supuran CT, Vizeacoumar FJ, and Dedhar S
- Subjects
- Carbon-Sulfur Lyases, Carbonic Anhydrase IX, Cell Hypoxia, Cell Line, Tumor, Humans, Hypoxia, Iron, Bicarbonates, Neoplasms genetics
- Abstract
The metabolic mechanisms involved in the survival of tumor cells within the hypoxic niche remain unclear. We carried out a synthetic lethal CRISPR screen to identify survival mechanisms governed by the tumor hypoxia-induced pH regulator carbonic anhydrase IX (CAIX). We identified a redox homeostasis network containing the iron-sulfur cluster enzyme, NFS1. Depletion of NFS1 or blocking cyst(e)ine availability by inhibiting xCT, while targeting CAIX, enhanced ferroptosis and significantly inhibited tumor growth. Suppression of CAIX activity acidified intracellular pH, increased cellular reactive oxygen species accumulation, and induced susceptibility to alterations in iron homeostasis. Mechanistically, inhibiting bicarbonate production by CAIX or sodium-driven bicarbonate transport, while targeting xCT, decreased adenosine 5'-monophosphate-activated protein kinase activation and increased acetyl-coenzyme A carboxylase 1 activation. Thus, an alkaline intracellular pH plays a critical role in suppressing ferroptosis, a finding that may lead to the development of innovative therapeutic strategies for solid tumors to overcome hypoxia- and acidosis-mediated tumor progression and therapeutic resistance., (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).)
- Published
- 2021
- Full Text
- View/download PDF
16. Hydrogen-deuterium exchange mass spectrometry reveals three unique binding responses of mAbs directed to the catalytic domain of hCAIX.
- Author
-
Sheff JG, Kelly JF, Robotham A, Sulea T, Malenfant F, L'Abbé D, Duchesne M, Pelletier A, Lefebvre J, Acel A, Parat M, Gosselin M, Wu C, Fortin Y, Baardsnes J, Van Faassen H, Awrey S, Chafe SC, McDonald PC, Dedhar S, and Lenferink AEG
- Subjects
- Antibodies, Monoclonal chemistry, Catalytic Domain, Deuterium chemistry, Epitope Mapping methods, Humans, Deuterium Exchange Measurement methods, Hydrogen Deuterium Exchange-Mass Spectrometry
- Abstract
Human carbonic anhydrase (hCAIX), an extracellular enzyme that catalyzes the reversible hydration of CO
2 , is often overexpressed in solid tumors. This enzyme is instrumental in maintaining the survival of cancer cells in a hypoxic and acidic tumor microenvironment. Absent in most normal tissues, hCAIX is a promising therapeutic target for detection and treatment of solid tumors. Screening of a library of anti-hCAIX monoclonal antibodies (mAbs) previously identified three therapeutic candidates (mAb c2C7, m4A2 and m9B6) with distinct biophysical and functional characteristics. Selective binding to the catalytic domain was confirmed by yeast surface display and isothermal calorimetry, and deeper insight into the dynamic binding profiles of these mAbs upon binding were highlighted by bottom-up hydrogen-deuterium exchange mass spectrometry (HDX-MS). Here, a conformational and allosterically silent epitope was identified for the antibody-drug conjugate candidate c2C7. Unique binding profiles are described for both inhibitory antibodies, m4A2 and m9B6. M4A2 reduces the ability of the enzyme to hydrate CO2 by steric gating at the entrance of the catalytic cavity. Conversely, m9B6 disrupts the secondary structure that is necessary for substrate binding and hydration. The synergy of these two inhibitory mechanisms is demonstrated in in vitro activity assays and HDX-MS. Finally, the ability of m4A2 to modulate extracellular pH and intracellular metabolism is reported. By highlighting three unique modes by which hCAIX can be targeted, this study demonstrates both the utility of HDX-MS as an important tool in the characterization of anti-cancer biotherapeutics, and the underlying value of CAIX as a therapeutic target.- Published
- 2021
- Full Text
- View/download PDF
17. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.
- Author
-
Brown WS, McDonald PC, Nemirovsky O, Awrey S, Chafe SC, Schaeffer DF, Li J, Renouf DJ, Stanger BZ, and Dedhar S
- Subjects
- Animals, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal genetics, Cell Line, Tumor, Cell Proliferation drug effects, Cell Proliferation genetics, Female, Gene Expression Regulation, Neoplastic drug effects, Gene Expression Regulation, Neoplastic genetics, Humans, Mice, Mice, Inbred C57BL, Mice, Inbred NOD, Mice, SCID, Mutation drug effects, Mutation genetics, Pancreatic Ducts drug effects, Pancreatic Neoplasms drug therapy, Phosphorylation drug effects, Phosphorylation genetics, Protein Kinase Inhibitors pharmacology, Signal Transduction drug effects, Signal Transduction genetics, Pancreatic Neoplasms, MAP Kinase Signaling System genetics, Mechanistic Target of Rapamycin Complex 1 genetics, Mechanistic Target of Rapamycin Complex 2 genetics, Mitogen-Activated Protein Kinase Kinases genetics, Pancreatic Neoplasms genetics, Proto-Oncogene Proteins p21(ras) genetics
- Abstract
Activating KRAS mutations are found in over 90% of pancreatic ductal adenocarcinomas (PDACs), yet KRAS has remained a difficult target to inhibit pharmacologically. Here, we demonstrate, using several human and mouse models of PDACs, rapid acquisition of tumor resistance in response to targeting KRAS or MEK, associated with integrin-linked kinase (ILK)-mediated increased phosphorylation of the mTORC2 component Rictor, and AKT. Although inhibition of mTORC1/2 results in a compensatory increase in ERK phosphorylation, combinatorial treatment of PDAC cells with either KRAS (G12C) or MEK inhibitors, together with mTORC1/2 inhibitors, results in synergistic cytotoxicity and cell death reflected by inhibition of pERK and pRictor/pAKT and of downstream regulators of protein synthesis and cell survival. Relative to single agents alone, this combination leads to durable inhibition of tumor growth and metastatic progression in vivo and increased survival. We have identified an effective combinatorial treatment strategy using clinically viable inhibitors, which can be applied to PDAC tumors with different KRAS mutations., Competing Interests: The authors declare no competing interests., (© 2020 The Author(s).)
- Published
- 2020
- Full Text
- View/download PDF
18. Training and education of pediatric radiation oncologists: A survey from the 2019 Pediatric Radiation Oncology Society meeting.
- Author
-
Paulino AC, Dieckmann K, Esiashvili N, Mahajan A, Janssens GO, Halperin EC, Carrie C, Parkes J, Wolden SL, Seiersen K, Awrey S, Dieter-Kortmann R, and Marcus KJ
- Subjects
- Child, Female, Humans, Male, Surveys and Questionnaires, Attitude of Health Personnel, Education, Medical, Continuing standards, Neoplasms radiotherapy, Pediatrics education, Radiation Oncologists education, Radiation Oncology education
- Abstract
To examine the educational background, clinical practice, and preferences regarding continuing medical education (CME) among radiation oncologists who attended the 2019 meeting of the Pediatric Radiation Oncology Society (PROS), a survey consisting of 20 questions was distributed asking for demographic and educational background, clinical practice, and preferences regarding pediatric radiation oncology CME. Of 188 participants, 130 (69.2%) returned the questionnaire. More than 80% reported access to CT simulation, three-dimensional radiotherapy, and general anesthesia while <30% had access to intraoperative radiotherapy, proton, and heavy particle therapy. After residency, 12.1% did further training in pediatric radiation oncology. When asked about further training in pediatrics after residency, 88.8% answered that there should be a formal training program beyond residency in order to treat children. More than 75% acquired knowledge in pediatric radiation oncology through journals, books, live meetings, and tumor boards. The results of this survey may help Pediatric Radiation Oncology Society (PROS) in creating guidelines and recommendations for improvement in pediatric radiation oncology training and practice support as well as the development of CME activities most likely to benefit practitioners., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
19. Minimizing General Anesthetic Use in Pediatric Radiation Therapy.
- Author
-
Ntoukas SM, Ritchie T, Awrey S, Hodgson DC, Laperriere N, Yee R, Ramaswamy V, Millar BA, Becker N, and Tsang DS
- Subjects
- Anesthesia, General methods, Child, Child, Preschool, Female, Humans, Male, Anesthesia, General adverse effects, Radiotherapy methods
- Abstract
Purpose: At our institution, a multifaceted approach is used to reduce general anesthetic (GA) use for children receiving photon radiation therapy (RT) as standard-of-care treatment. The purpose of this study was to evaluate the effectiveness of our methods., Methods and Materials: Patients treated as part of the pediatric radiation therapy program from 2010 to 2018 were retrospectively reviewed. GA use was defined as need for intravenous propofol or inhaled gaseous anesthetic for at least 1 simulation or RT session. Methods to reduce GA use included presence of a dedicated pediatric nurse for procedural preparation, audiovisual distraction (television during RT), and 2-way audio communication with caregivers., Results: There were 779 unique patients who received RT over 14 163 fractions of radiation. GA utilization was 90% in those under age 3, 28% in those age 3 to 6, 1% in those age 7 to 11, and <1% in those ≥12 years of age. Four years of age is a cutoff age at which the majority of patients switch from needing GA (56.6% for those aged 3) to not needing GA (29.8% for those aged 4). Younger age, use of total body irradiation, and craniospinal irradiation were independently associated with requiring GA., Conclusions: Using methods designed to reduce GA use, most children aged 4 years or older were able receive RT awake. Our GA rates compare favorably to other literature reports; thus, pediatric RT centers should consider adopting specific interventions to reduce GA use., (Copyright © 2019 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
20. Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts.
- Author
-
Hedlund EE, McDonald PC, Nemirovsky O, Awrey S, Jensen LDE, and Dedhar S
- Abstract
Triple Negative Breast Cancer (TNBC) is aggressive, metastatic and drug-resistant, limiting the spectrum of effective therapeutic options for breast cancer patients. To date, anti-angiogenic agents have had limited success in the treatment of systemic breast cancer, possibly due to the exacerbation of tumor hypoxia and increased metastasis. Hypoxia drives increased expression of downstream effectors, including Carbonic Anhydrase IX (CAIX), a critical functional component of the pro-survival machinery required by hypoxic tumor cells. Here, we used the highly metastatic, CAIX-positive MDA-MB-231 LM2-4 orthotopic model of TNBC to investigate whether combinatorial targeting of CAIX and angiogenesis impacts tumor growth and metastasis in vivo to improve efficacy. The administration of a small molecule inhibitor of CAIX, SLC-0111, significantly reduced overall metastatic burden, whereas exposure to sunitinib increased hypoxia and CAIX expression in primary tumors, and failed to inhibit metastasis. The administration of SLC-0111 significantly decreased primary tumor vascular density and permeability, and reduced metastasis to the lung and liver. Furthermore, combining sunitinib and SLC-0111 significantly reduced both primary tumor growth and sunitinib-induced metastasis to the lung. Our findings suggest that targeting angiogenesis and hypoxia effectors in combination holds promise as a novel rational strategy for the effective treatment of patients with TNBC., Competing Interests: P.C.M. and S.D. are inventors of SLC-0111. All other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
- Published
- 2019
- Full Text
- View/download PDF
21. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
- Author
-
Lallous N, Leblanc E, Munuganti RS, Hassona MD, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns ES, Rennie PS, and Cherkasov A
- Subjects
- Androgen Receptor Antagonists chemistry, Animals, Benzamides, Biomarkers, Tumor, Cell Line, Tumor, Cell Survival drug effects, Disease Models, Animal, Dose-Response Relationship, Drug, Gene Expression Regulation, Neoplastic drug effects, Humans, Male, Mice, Molecular Conformation, Molecular Docking Simulation, Molecular Dynamics Simulation, Nitriles, Phenylthiohydantoin analogs & derivatives, Phenylthiohydantoin pharmacology, Prostatic Neoplasms drug therapy, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology, Protein Binding drug effects, Protein Transport drug effects, Receptors, Androgen chemistry, Signal Transduction drug effects, Transcription, Genetic drug effects, Xenograft Model Antitumor Assays, Androgen Receptor Antagonists pharmacology, Carrier Proteins metabolism, Protein Interaction Domains and Motifs, Receptors, Androgen metabolism
- Abstract
The development of new antiandrogens, such as enzalutamide, or androgen synthesis inhibitors like abiraterone has improved patient outcomes in the treatment of advanced prostate cancer. However, due to the development of drug resistance and tumor cell survival, a majority of these patients progress to the refractory state of castration-resistant prostate cancer (CRPC). Thus, newer therapeutic agents and a better understanding of their mode of action are needed for treating these CRPC patients. We demonstrated previously that targeting the Binding Function 3 (BF3) pocket of the androgen receptor (AR) has great potential for treating patients with CRPC. Here, we explore the functional activity of this site by using an advanced BF3-specific small molecule (VPC-13566) that was previously reported to effectively inhibit AR transcriptional activity and to displace the BAG1L peptide from the BF3 pocket. We show that VPC-13566 inhibits the growth of various prostate cancer cell lines, including an enzalutamide-resistant cell line, and reduces the growth of AR-dependent prostate cancer xenograft tumors in mice. Importantly, we have used this AR-BF3 binder as a chemical probe and identified a co-chaperone, small glutamine-rich tetratricopeptide repeat (TPR)-containing protein alpha (SGTA), as an important AR-BF3 interacting partner. Furthermore, we used this AR-BF3-directed small molecule to demonstrate that inhibition of AR activity through the BF3 functionality can block translocation of the receptor into the nucleus. These findings suggest that targeting the BF3 site has potential clinical importance, especially in the treatment of CRPC and provide novel insights on the functional role of the BF3 pocket. Mol Cancer Ther; 15(12); 2936-45. ©2016 AACR., Competing Interests: The authors disclose no potential conflicts of interest., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
22. Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy.
- Author
-
Hayashi T, Gust KM, Wyatt AW, Goriki A, Jäger W, Awrey S, Li N, Oo HZ, Altamirano-Dimas M, Buttyan R, Fazli L, Matsubara A, and Black PC
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation genetics, Enzyme Activation genetics, Gene Dosage genetics, Humans, Lymphatic Metastasis genetics, Mice, Neoplasm Invasiveness genetics, RNA Interference, RNA, Small Interfering genetics, Receptor, Notch1 biosynthesis, Receptor, Notch2 antagonists & inhibitors, Receptor, Notch3 biosynthesis, Signal Transduction genetics, Xenograft Model Antitumor Assays, Epithelial-Mesenchymal Transition genetics, Receptor, Notch2 genetics, Receptor, Notch2 metabolism, Urinary Bladder Neoplasms pathology
- Abstract
Purpose: Recent molecular analyses of bladder cancer open the door to significant advances in targeted therapies. NOTCH has been identified as a tumor suppressor in bladder cancer, but prior reports have focused on NOTCH1 Here we hypothesized that NOTCH2 is an oncogene suitable for therapeutic targeting in bladder cancer., Experimental Design: We studied genomic aberrations of NOTCH, compared survival and tumor progression according to NOTCH2 expression levels, and studied NOTCH2 function in vitro and vivo, Results: We report a high rate of NOTCH2 copy number gain in bladder cancer. High NOTCH2 expression was identified especially in the basal subtype and in mesenchymal tumors. NOTCH2 activation correlated with adverse disease parameters and worse prognosis by immunohistochemistry. Forced overexpression of the intracellular domain of NOTCH2 (N2ICD) induced cell growth and invasion by cell-cycle progression, maintenance of stemness and epithelial-to-mesenchymal transition (EMT). These effects were abrogated by silencing of CSL, indicating that the effects were mediated through the canonical NOTCH signaling pathway. In an orthotopic xenograft model, forced overexpression of N2ICD increased growth, invasion, and metastasis. To explore the potential for therapeutic targeting of NOTCH2, we first silenced the receptor with shRNA and subsequently treated with a specific inhibitory antibody. Both interventions decreased cell growth, invasion, and metastasis in vitro and in the orthotopic xenograft model., Conclusions: We have demonstrated that NOTCH2 acts as an oncogene that promotes bladder cancer growth and metastasis through EMT, cell-cycle progression, and maintenance of stemness. Inhibition of NOTCH2 is a rational novel treatment strategy for invasive bladder cancer. Clin Cancer Res; 22(12); 2981-92. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
23. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
- Author
-
Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, and Cherkasov A
- Subjects
- Androgen Receptor Antagonists therapeutic use, Anilides pharmacology, Benzamides, DNA blood, Flutamide analogs & derivatives, Flutamide pharmacology, High-Throughput Nucleotide Sequencing, Humans, Male, Mutation genetics, Nitriles pharmacology, Phenylthiohydantoin analogs & derivatives, Phenylthiohydantoin pharmacology, Prostatic Neoplasms, Castration-Resistant drug therapy, Prostatic Neoplasms, Castration-Resistant pathology, Tosyl Compounds pharmacology, DNA genetics, Drug Resistance, Neoplasm genetics, Prostatic Neoplasms, Castration-Resistant genetics, Receptors, Androgen genetics
- Abstract
Background: The androgen receptor (AR) is a pivotal drug target for the treatment of prostate cancer, including its lethal castration-resistant (CRPC) form. All current non-steroidal AR antagonists, such as hydroxyflutamide, bicalutamide, and enzalutamide, target the androgen binding site of the receptor, competing with endogenous androgenic steroids. Several AR mutations in this binding site have been associated with poor prognosis and resistance to conventional prostate cancer drugs. In order to develop an effective CRPC therapy, it is crucial to understand the effects of these mutations on the functionality of the AR and its ability to interact with endogenous steroids and conventional AR inhibitors., Results: We previously utilized circulating cell-free DNA (cfDNA) sequencing technology to examine the AR gene for the presence of mutations in CRPC patients. By modifying our sequencing and data analysis approaches, we identify four additional single AR mutations and five mutation combinations associated with CRPC. Importantly, we conduct experimental functionalization of all the AR mutations identified by the current and previous cfDNA sequencing to reveal novel gain-of-function scenarios. Finally, we evaluate the effect of a novel class of AR inhibitors targeting the binding function 3 (BF3) site on the activity of CRPC-associated AR mutants., Conclusions: This work demonstrates the feasibility of a prognostic and/or diagnostic platform combining the direct identification of AR mutants from patients' serum, and the functional characterization of these mutants in order to provide personalized recommendations regarding the best future therapy.
- Published
- 2016
- Full Text
- View/download PDF
24. Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.
- Author
-
Hayashi T, Seiler R, Oo HZ, Jäger W, Moskalev I, Awrey S, Dejima T, Todenhöfer T, Li N, Fazli L, Matsubara A, and Black PC
- Subjects
- Ado-Trastuzumab Emtansine, Animals, Apoptosis, Disease Models, Animal, Female, Gene Expression Regulation, Neoplastic, Humans, Male, Maytansine pharmacology, Mice, Tumor Cells, Cultured, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents pharmacology, Maytansine analogs & derivatives, Receptor, ErbB-2 biosynthesis, Receptor, ErbB-2 drug effects, Trastuzumab pharmacology, Urinary Bladder Neoplasms metabolism
- Abstract
Purpose: Systemic therapy for advanced bladder cancer has not changed substantially in more than 2 decades and mortality rates remain high. The recognition of HER2 over expression in bladder cancer has made HER2 a promising therapeutic target. T-DM1, a new drug consisting of the HER2 antibody trastuzumab conjugated with a cytotoxic agent, has been shown in breast cancer to be superior to trastuzumab. We tested T-DM1 in preclinical models of bladder cancer., Materials and Methods: We evaluated the effect of T-DM1 compared to trastuzumab in different in vitro and in vivo models of HER2 over expressing bladder cancer., Results: RT4V6 was the highest HER2 expressing bladder cancer cell line and it showed higher growth inhibition with T-DM1 compared to trastuzumab. T-DM1 but not trastuzumab induced apoptosis of RT4V6 cells after G2/M arrest on cell cycle analysis. HER2 expression was higher in cell lines with acquired cisplatin resistance compared to the corresponding parental cell lines. Resistant cells showed higher sensitivity to T-DM1 by the induction of apoptosis. In addition, cells cultured in anchorage independent conditions increased HER2 expression compared to cells cultured in adherent conditions and T-DM1 significantly inhibited colony formation in soft agar compared to trastuzumab. In an orthotopic bladder cancer xenograft model tumor growth of cisplatin resistant RT112 was significantly inhibited by T-DM1 via the induction of apoptosis compared to treatment with control IgG or trastuzumab., Conclusions: T-DM1 has promising antitumor effects in preclinical models of HER2 over expressing bladder cancer., (Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
25. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
- Author
-
Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, Anderson S, Moskalev I, Haegert A, Alshalalfa M, Erho N, Davicioni E, Fazli L, Li E, Collins C, Wang Y, and Black PC
- Subjects
- Aged, Animals, Comparative Genomic Hybridization, DNA Copy Number Variations, DNA Mutational Analysis, Disease Models, Animal, Female, Humans, Immunohistochemistry, Male, Mice, Mice, Inbred NOD, Mice, SCID, Middle Aged, Mutation, Oligonucleotide Array Sequence Analysis, Receptor, Fibroblast Growth Factor, Type 3 genetics, Urinary Bladder Neoplasms genetics, Neoplasm Transplantation, Urinary Bladder Neoplasms pathology, Xenograft Model Antitumor Assays
- Abstract
Optimal animal models of muscle invasive bladder cancer (MIBC) are necessary to overcome the current lack of novel targeted therapies for this malignancy. Here we report on the establishment and characterization of patient-derived primary xenografts (PDX). Patient tumors were grafted under the renal capsule of mice and subsequently transplanted over multiple generations. Patient tumor and PDX were processed for analysis of copy number variations by aCGH, gene expression by microarray, and expression of target pathways by immunohistochemistry (IHC). One PDX harbouring an FGFR3 mutation was treated with an inhibitory monoclonal antibody targeting FGFR3. Five PDX were successfully established. Tumor doubling time ranged from 5 to 11 days. Array CGH revealed shared chromosomal aberrations in the patient tumors and PDX. Gene expression microarray and IHC confirmed that PDXs maintain similar patterns to the parental tumors. Tumor growth in the PDX with an FGFR3 mutation was inhibited by the FGFR3 inhibitor. PDXs recapitulate the tumor biology of the patients' primary tumors from which they are derived. Investigations related to tumor biology and drug testing in these models are therefore more likely to be relevant to the disease state in patients. They represent a valuable tool for developing precision therapy in MIBC.
- Published
- 2015
- Full Text
- View/download PDF
26. Minimally invasive establishment of murine orthotopic bladder xenografts.
- Author
-
Jäger W, Moskalev I, Janssen C, Hayashi T, Gust KM, Awrey S, and Black PC
- Subjects
- Animals, Cell Line, Tumor, Disease Models, Animal, Female, Humans, Mice, Neoplasm Transplantation methods, Transplantation, Heterologous methods, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms surgery
- Abstract
Orthotopic bladder cancer xenografts are the gold standard to study molecular cellular manipulations and new therapeutic agents in vivo. Suitable cell lines are inoculated either by intravesical instillation (model of nonmuscle invasive growth) or intramural injection into the bladder wall (model of invasive growth). Both procedures are complex and highly time-consuming. Additionally, the superficial model has its shortcomings due to the lack of cell lines that are tumorigenic following instillation. Intramural injection, on the other hand, is marred by the invasiveness of the procedure and the associated morbidity for the host mouse. With these shortcomings in mind, we modified previous methods to develop a minimally invasive approach for creating orthotopic bladder cancer xenografts. Using ultrasound guidance we have successfully performed percutaneous inoculation of the bladder cancer cell lines UM-UC1, UM-UC3 and UM-UC13 into 50 athymic nude. We have been able to demonstrate that this approach is time efficient, precise and safe. With this technique, initially a space is created under the bladder mucosa with PBS, and tumor cells are then injected into this space in a second step. Tumor growth is monitored at regular intervals with bioluminescence imaging and ultrasound. The average tumor volumes increased steadily in in all but one of our 50 mice over the study period. In our institution, this novel approach, which allows bladder cancer xenograft inoculation in a minimally-invasive, rapid and highly precise way, has replaced the traditional model.
- Published
- 2014
- Full Text
- View/download PDF
27. Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa.
- Author
-
Jäger W, Horiguchi Y, Shah J, Hayashi T, Awrey S, Gust KM, Hadaschik BA, Matsui Y, Anderson S, Bell RH, Ettinger S, So AI, Gleave ME, Lee IL, Dinney CP, Tachibana M, McConkey DJ, and Black PC
- Subjects
- Comparative Genomic Hybridization, Gene Expression Profiling, Humans, Time Factors, Urinary Bladder Neoplasms pathology, DNA Contamination, HeLa Cells
- Abstract
Purpose: KU7 is a popular urothelial carcinoma cell line that was isolated from the bladder of a patient at Keio University in 1980. It has subsequently been widely used in laboratories around the world. We describe how routine cell line authentication revealed that KU7 was cross contaminated almost 30 years ago with HeLa, a cervical carcinoma cell line., Materials and Methods: Presumed KU7 clones dating from 1984 to 1999 were provided by M.D. Anderson Cancer Center, Vancouver Prostate Centre, Kyoto University, Tokyo Medical University and Keio University. HeLa was obtained from ATCC. Genomic DNA was isolated and short tandem repeat analysis was performed at the M.D. Anderson Cancer Center Characterized Cell Line Core Facility, Johns Hopkins University Fragment Analysis Facility and RIKEN BioResource Center, Ibaraki, Japan. Comparative genomic hybridization was performed on a platform (Agilent Technologies, Santa Clara, California) at Vancouver Prostate Centre., Results: The short tandem repeat profile of all KU7 clones was an exact match with that of HeLa. Comparative genomic hybridization of all samples revealed an abundance of shared chromosomal aberrations. Slight differences in some genomic areas were explained by genomic drift in different KU7 clones separated by many years., Conclusions: Our analysis identified that cross contamination of KU7 with HeLa occurred before 1984 at the source institution. All KU7 clones in the urological literature should be considered HeLa and experimental results should be viewed in this light. Our results emphasize the need to authenticate cell lines in oncological research., (Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
28. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.
- Author
-
Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, Ashkenazi A, Czerniak B, Dinney CP, and Black PC
- Subjects
- Adult, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal immunology, Apoptosis drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Humans, Immunohistochemistry, Male, Mice, Mice, Nude, Middle Aged, Molecular Targeted Therapy, Xenograft Model Antitumor Assays, Antibodies, Monoclonal pharmacology, Receptor, Fibroblast Growth Factor, Type 3 immunology, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms immunology
- Abstract
Activating mutations of fibroblast growth factor receptor-3 (FGFR3) have been described in approximately 75% of low-grade papillary bladder tumors. In muscle-invasive disease, FGFR3 mutations are found in 20% of tumors, but overexpression of FGFR3 is observed in about half of cases. Therefore, FGFR3 is a particularly promising target for therapy in bladder cancer. Up to now, most drugs tested for inhibition of FGFR3 have been small molecule, multityrosine kinase inhibitors. More recently, a specific inhibitory monoclonal antibody targeting FGFR3 (R3Mab) has been described and tested preclinically. In this study, we have evaluated mutation and expression status of FGFR3 in 19 urothelial cancer cell lines and a cohort of 170 American patients with bladder cancer. We have shown inhibitory activity of R3Mab on tumor growth and corresponding cell signaling in three different orthotopic xenografts of bladder cancer. Our results provide the preclinical proof of principle necessary to translate FGFR3 inhibition with R3Mab into clinical trials in patients with bladder cancer.
- Published
- 2013
- Full Text
- View/download PDF
29. Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach.
- Author
-
Jäger W, Moskalev I, Janssen C, Hayashi T, Awrey S, Gust KM, So AI, Zhang K, Fazli L, Li E, Thüroff JW, Lange D, and Black PC
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation, Feasibility Studies, Female, Humans, Mice, Oncolytic Viruses physiology, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms virology, Surgery, Computer-Assisted methods, Transplantation, Heterologous methods, Ultrasonics, Urinary Bladder Neoplasms pathology
- Abstract
Orthotopic bladder cancer xenografts are essential for testing novel therapies and molecular manipulations of cell lines in vivo. Current xenografts rely on tumor cell inoculation by intravesical instillation or direct injection into the bladder wall. Instillation is limited by the lack of cell lines that are tumorigenic when delivered in this manner. The invasive model inflicts morbidity on the mice by the need for laparotomy and mobilization of the bladder. Furthermore this procedure is complex and time-consuming. Three bladder cancer cell lines (UM-UC1, UM-UC3, UM-UC13) were inoculated into 50 athymic nude mice by percutaneous injection under ultrasound guidance. PBS was first injected between the muscle wall and the mucosa to separate these layers, and tumor cells were subsequently injected into this space. Bioluminescence and ultrasound were used to monitor tumor growth. Contrast-enhanced ultrasound was used to study changes in tumor perfusion after systemic gemcitabine/cisplatin treatment. To demonstrate proof of principle that therapeutic agents can be injected into established xenografts under ultrasound guidance, oncolytic virus (VSV) was injected into UM-UC3 tumors. Xenograft tissue was harvested for immunohistochemistry after 23-37 days. Percutaneous injection of tumor cells into the bladder wall was performed efficiently (mean time: 5.7 min) and without complications in all 50 animals. Ultrasound and bioluminescence confirmed presence of tumor in the anterior bladder wall in all animals 3 days later. The average tumor volumes increased steadily over the study period. UM-UC13 tumors showed a marked decrease in volume and perfusion after chemotherapy. Immunohistochemical staining for VSV-G demonstrated virus uptake in all UM-UC3 tumors after intratumoral injection. We have developed a novel method for creating orthotopic bladder cancer xenograft in a minimally invasive fashion. In our hands this has replaced the traditional model requiring laparotomy, because this model is more time efficient, more precise and associated with less morbidity for the mice.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.